Results 81 to 90 of about 443,266 (297)
Report of the 2003 National Conference on Public Health and Epilepsy [PDF]
I. Executive Summary -- II. Introduction -- III. Living Well with Epilepsy II Conference -- -- IV. Review and Recommendations -- -- Workgroup A: Early Recognition, Diagnosis and Treatment -- -- Workgroup B: Epidemiology and Surveillance -- -- Workgroup C:
National Conference on Public Health and Epilepsy (2003 : Baltimore, MD)
core
Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Dravet Syndrome (DS) is a developmental and epileptic encephalopathy predominantly caused by heterozygous loss‐of‐function variants in SCN1A, which encodes Nav1.1. Conserved upstream open reading frames (uORFs) in SCN1A were validated to regulate translation in reporter assays, demonstrating the therapeutic viability of increasing Nav1.1 from ...
Aiswarya Saravanan +7 more
wiley +1 more source
, 2009 To compare the health-related quality of life (HRQL) for patients with epilepsy and health subjects, we collected the clinical and demographic data and information on health states by using the Taiwan version of World Health Organization quality of life (
LIOU, HORNG-HUEI;CHEN, RONG-CHI;CHEN, CHIH-CHUAN;CHIU, MING-JANG;CHANG, YU-YIN;WANG, JUNG-DER +1 more
core +1 more source
Examining and improving knowledge and attitudes about epilepsy has been a public health priority because of stigma around the disorder. This study had three goals: (1) to update estimates describing U.S.
core +8 more sources
Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son +3 more
wiley +1 more source
Epilepsia OpenObjective Sudden unexpected death in epilepsy (SUDEP) is a rare but devastating consequence of epilepsy and is the leading cause of death in people with epilepsy.
Sloka S. Iyengar +6 more
doaj +1 more source
Chinese expert consensus on disclosure of sudden unexpected death in epilepsy
Chinese Journal of Contemporary Neurology and NeurosurgerySudden unexpected death in epilepsy (SUDEP) refers to the sudden, unexpected, and witnessed or unwitnessed death of a patient with epilepsy, with or without evidence of a seizure, excluding status epilepticus, non-traumatic and non-drowning causes, and ...
Comorbidity Committee of China Association Against Epilepsy
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background We aimed to identify the proportion of individuals with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) who show a negative routine EEG (rEEG), and to determine the main factors associated with this finding.
Francesco Fortunato +7 more
wiley +1 more source
Report of the 1997 National Conference on Public Health and Epilepsy [PDF]
"In late 1994, the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) within the Centers for Disease Control and Prevention (CDC) convened a group of experts representing the epilepsy treatment and advocacy communities to help ...
National Conference on Public Health and Epilepsy (1997 : Orlando, FL)
core